RxDoctor Payments DataLook up a doctor →

Daniel Ibarra-Taylor, PA

Physician Assistant · Riverton, UTNPI 1740514892

Payments from drug & device makers

$10,869in general payments, 2019–2025

Across 699 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$795
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$708
  • Nestle Healthcare Nutrition Inc.$420
  • Pfizer$315
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$10,76499%
  • Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,869 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$44,044
Medicare patients
224
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide11$510,320
Humira(Cf) PenAdalimumab15$190,563
LinzessLinaclotide201$140,997
ZenpepLipase/Protease/Amylase15$63,021
CreonLipase/Protease/Amylase13$59,135
XifaxanRifaximin16$52,931
TrulancePlecanatide30$29,466
IbsrelaTenapanor Hcl11$21,862
Mesalamine18$12,253
MovantikNaloxegol Oxalate25$10,163
Omeprazole247$5,450
Sucralfate65$4,661
Colestipol Hcl92$3,830
Dicyclomine Hcl150$3,411
Balsalazide Disodium23$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$1,009$510,32011 claims
AbbVieLinzess, Creon$4,315$200,132214 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$708$82,39846 claims
Aimmune Therapeutics, Inc.Zenpep$184$63,02115 claims
Ardelyx, Inc.Ibsrela$254$21,86211 claims
Redhill Biopharma Inc.Movantik$106$10,16325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →